[Biomarker for chemotherapy in patients with colorectal cancer]

Prognostic, predictive and safety biomarkers of chemotherapy for colorectal cancer have been reported. Recently, it was reported that KRAS mutation was present in 27-43% of patients, was associated with resistance to antibody against the epidermal growth factor receptor(EGFR), and showed a poorer survival in metastatic colorectal cancer. The search for biomarkers is therefore being conducted vigorously in parallel with a number of clinical trials that are currently being conducted for new drugs. We believe that future areas of research will include the establishment of clinical evidence through large-scale clinical trials and the standardization of analysis protocols.